Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Plus, news about MindMed, Ven­tyx Bio­sciences, Rakuten Med­ical and Ross Ac­qui­si­tion Corp:

Ul­ti­movacs’ melanoma vac­cine flops in PhII: When added to Bris­tol My­ers Squibb’s Yer­voy and Op­di­vo, the ex­per­i­men­tal UV1 vac­cine did not meet pri­ma­ry or sec­ondary end­points ver­sus the two check­point in­hibitors in un­re­sectable or metasta­t­ic melanoma. The com­pa­ny’s stock $UL­TI.OL, list­ed on the Oslo Stock Ex­change, dropped about 92% on Thurs­day. The biotech said it will con­tin­ue to test UV1 in oth­er com­bi­na­tions and can­cers. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER